LogicBio Therapeutics Inc (LOGC)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

65 HAYDEN AVE LEXINGTON, MA 02421

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.

Data as of 2021-07-19 09:50:19 -0400
Market Cap128.963 Million Shares Outstanding32.16 Million Avg 30-day Volume266.054 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE12.81 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.14262 52-week High/Low10.0 / 3.72 Next Earnings Date2021-08-09 Price to Cash FLow (P/CF) -13.834
Data provided by IEX Cloud

Are you looking for this stock instead?

View SEC Filings from LOGC instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 60 59 1.69% 15 (0.88%) 16 (0.93%) -6.25%
13F shares: 17.627 Million 17.396 Million 1.33% 12.401 Million 12.478 Million -0.61%
% Ownership 55.0393 54.7287 0.57% 38.7211 39.2542 -1.36%
New Positions: 11 14 -21.43% 4 6 -33.33%
Increased Positions 17 26 -34.62% 3 6 -50.0%
Closed Positions 9 5 80.0% 5 1 400.0%
Reduced Positions 14 6 133.33% 4 1 300.0%
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LOGC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LOGC BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KAY MARK A

  • Director
5,000 2021-06-18 3

CHEN LEON

  • Director
12,500 2021-06-11 2

MOSCICKI RICHARD A

  • Director
12,500 2021-06-11 2

WYZGA MICHAEL S

  • Director
12,500 2021-06-11 2

ENYEDY MARK J

  • Director
12,500 2021-06-11 2

GOATER JEFF

  • Director
12,500 2021-06-11 3

KARYDAS DAPHNE

  • Director
12,500 2021-06-11 3

GRUSKIN DANIEL CHIEF MEDICAL OFFICER

  • Officer
0 2021-05-19 2

PAUL ANDREA GENERAL COUNSEL AND SECRETARY

  • Officer
165,000 2021-05-17 2

CHEREAU FREDERIC PRESIDENT AND CHIEF EXECUTIVE

  • Officer
  • Director
515,164 2021-04-15 2

CHIANG KYLE CHIEF OPERATING OFFICER

  • Officer
49,751 2021-04-15 4

JONES CECILIA CHIEF FINANCIAL OFFICER

  • Officer
78,000 2021-02-23 3

QUICK JONATHAN SENIOR DIRECTOR-FINANCE

  • Officer
0 2021-01-01 1

O'CONNELL DANIEL P

  • Director
No longer subject to file 2020-12-10 1

NACHT MARIANA CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-11-30 2

CHIMOVITS EREZ

  • Director
  • 10% Owner
7,948,265 2020-10-01 1

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

ORBIMED ADVISORS ISRAEL II LTD

ORBIMED ISRAEL GP II, L.P.

ORBIMED GENESIS GP LLC

  • Director
  • 10% Owner
7,948,265 2020-10-01 1

ARIX BIOSCIENCE PLC

ARIX BIOSCIENCE HOLDINGS LTD

  • 10% Owner
2,381,436 2020-07-16 0

YOON SEOKHO BRYAN CHIEF ADMIN OFFICER & GC

  • Officer
0 2020-04-15 0

JAFFE MATTHIAS CHIEF FINANCIAL OFFICER

  • Officer
0 2020-04-15 0

HUTTNER KENNETH SVP, HEAD OF CLINICAL DEV.

  • Officer
0 2020-02-11 0

KARIV TOMER

  • Director
0 2019-12-19 0

WILTON THOMAS CHIEF BUSINESS OFFICER

  • Officer
75,000 2019-08-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KAY MARK A - Director

2021-06-21 16:39:46 -0400 2021-06-18 A 5,000 a 5,000 direct

WYZGA MICHAEL S - Director

2021-06-14 20:00:30 -0400 2021-06-11 A 12,500 a 12,500 direct

GOATER JEFF - Director

2021-06-14 20:01:05 -0400 2021-06-11 A 12,500 a 12,500 direct

KAY MARK A - Director

2021-06-14 20:00:38 -0400 2021-06-11 A 12,500 a 12,500 direct

CHEN LEON - Director

2021-06-14 20:00:58 -0400 2021-06-11 A 12,500 a 12,500 direct

MOSCICKI RICHARD A - Director

2021-06-14 20:00:37 -0400 2021-06-11 A 12,500 a 12,500 direct

ENYEDY MARK J - Director

2021-06-14 20:01:06 -0400 2021-06-11 A 12,500 a 12,500 direct

KARYDAS DAPHNE - Director

2021-06-14 20:00:52 -0400 2021-06-11 A 12,500 a 12,500 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 22:15:03 UTC -0.9451 1.0251 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 21:45:03 UTC -0.9719 1.0519 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 21:15:03 UTC -0.9719 1.0519 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 20:45:03 UTC -1.1387 1.2187 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 20:15:05 UTC -1.1387 1.2187 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 19:45:03 UTC -1.1387 1.2187 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 19:15:03 UTC -1.1387 1.2187 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 18:45:03 UTC -1.2826 1.3626 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 18:15:03 UTC -1.2826 1.3626 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 17:45:03 UTC -1.2826 1.3626 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 17:15:02 UTC -1.2826 1.3626 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 16:45:02 UTC -2.4026 2.4826 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 16:15:03 UTC -2.4026 2.4826 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 15:45:02 UTC -2.4026 2.4826 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 15:15:03 UTC -2.4026 2.4826 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 14:45:03 UTC -2.5685 2.6485 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 14:15:03 UTC -2.5685 2.6485 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 13:45:03 UTC -2.5685 2.6485 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 13:15:03 UTC -2.5685 2.6485 1000000
LOGICBIO THERAPEUTICS INC LOGC 2021-07-23 12:45:03 UTC -2.5685 2.6485 950000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments